These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. The Cdh5-CreERT2 transgene causes conditional Shb gene deletion in hematopoietic cells with consequences for immune cell responses to tumors. He Q; Li X; Singh K; Luo Z; Meija-Cordova M; Jamalpour M; Lindahl B; Kriz V; Vuolteenaho R; Ulvmar M; Welsh M Sci Rep; 2019 May; 9(1):7548. PubMed ID: 31101877 [TBL] [Abstract][Full Text] [Related]
8. Identifying the variables that drive tamoxifen-independent CreERT2 recombination: Implications for microglial fate mapping and gene deletions. Van Hove H; Antunes ARP; De Vlaminck K; Scheyltjens I; Van Ginderachter JA; Movahedi K Eur J Immunol; 2020 Mar; 50(3):459-463. PubMed ID: 31785096 [TBL] [Abstract][Full Text] [Related]
9. Differential organ phenotypes after postnatal Igf1r gene conditional deletion induced by tamoxifen in UBC-CreERT2; Igf1r fl/fl double transgenic mice. López IP; Rodriguez-de la Rosa L; Pais RS; Piñeiro-Hermida S; Torrens R; Contreras J; Varela-Nieto I; Pichel JG Transgenic Res; 2015 Apr; 24(2):279-94. PubMed ID: 25238791 [TBL] [Abstract][Full Text] [Related]
10. Inducible gene deletion in the entire cardiac conduction system using Hcn4-CreERT2 BAC transgenic mice. Wu M; Peng S; Zhao Y Genesis; 2014 Feb; 52(2):134-40. PubMed ID: 24281837 [TBL] [Abstract][Full Text] [Related]
11. Temporal control of gene recombination in astrocytes by transgenic expression of the tamoxifen-inducible DNA recombinase variant CreERT2. Hirrlinger PG; Scheller A; Braun C; Hirrlinger J; Kirchhoff F Glia; 2006 Jul; 54(1):11-20. PubMed ID: 16575885 [TBL] [Abstract][Full Text] [Related]
13. Effects of CreERT2, 4-OH Tamoxifen, and Gender on CFU-F Assays. McHaffie SL; Hastie ND; Chau YY PLoS One; 2016; 11(2):e0148105. PubMed ID: 26828722 [TBL] [Abstract][Full Text] [Related]
14. Perinatal induction of Cre recombination with tamoxifen. Lizen B; Claus M; Jeannotte L; Rijli FM; Gofflot F Transgenic Res; 2015 Dec; 24(6):1065-77. PubMed ID: 26395370 [TBL] [Abstract][Full Text] [Related]
15. A powerful transgenic tool for fate mapping and functional analysis of newly generated neurons. Zhang J; Giesert F; Kloos K; Vogt Weisenhorn DM; Aigner L; Wurst W; Couillard-Despres S BMC Neurosci; 2010 Dec; 11():158. PubMed ID: 21194452 [TBL] [Abstract][Full Text] [Related]
16. Uncovering the fine print of the CreERT2-LoxP system while generating a conditional knockout mouse model of Ssrp1 gene. Sandlesh P; Juang T; Safina A; Higgins MJ; Gurova KV PLoS One; 2018; 13(6):e0199785. PubMed ID: 29953487 [TBL] [Abstract][Full Text] [Related]
17. Comparison of endothelial promoter efficiency and specificity in mice reveals a subset of Pdgfb-positive hematopoietic cells. Kilani B; Gourdou-Latyszenok V; Guy A; Bats ML; Peghaire C; Parrens M; Renault MA; Duplàa C; Villeval JL; Rautou PE; Couffinhal T; James C J Thromb Haemost; 2019 May; 17(5):827-840. PubMed ID: 30801958 [TBL] [Abstract][Full Text] [Related]
18. Genetic inducible fate mapping in adult mice using tamoxifen-dependent Cre recombinases. Feil S; Krauss J; Thunemann M; Feil R Methods Mol Biol; 2014; 1194():113-39. PubMed ID: 25064100 [TBL] [Abstract][Full Text] [Related]
19. Optimizing tamoxifen-inducible Cre/loxp system to reduce tamoxifen effect on bone turnover in long bones of young mice. Zhong ZA; Sun W; Chen H; Zhang H; Lay YE; Lane NE; Yao W Bone; 2015 Dec; 81():614-619. PubMed ID: 26232373 [TBL] [Abstract][Full Text] [Related]
20. Gene dose matters: Considerations for the use of inducible CD4-CreER Zeiträg J; Alterauge D; Dahlström F; Baumjohann D Eur J Immunol; 2020 Apr; 50(4):603-605. PubMed ID: 32087088 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]